We are live on
!
Find out more
Cardiff Oncology
CRDF
CRDF
48 hedge funds and large institutions have $4.25M invested in Cardiff Oncology in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 23 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.1% less ownership
Funds ownership: 0.25% → 0.15% (-0.1%)
23% less funds holding
Funds holding: 62 → 48 (-14)
34% less capital invested
Capital invested by funds: $6.47M → $4.25M (-$2.22M)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
70% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 23
Holders
48
Holders Change
-14
Holders Change %
-22.58%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
23
Closed
22
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$82K
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$228K |
| 2 |
Millennium Management
New York
|
+$220K |
| 3 |
ECM
Element Capital Management
New York
|
+$118K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$107K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$76K |
Top Sellers
| 1 |
BlackRock
New York
|
-$1.13M |
| 2 |
State Street
Boston,
Massachusetts
|
-$367K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$262K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$233K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$178K |
